PHRM.C

Top 5 Gainers and Losers: RPX.V, NINE.CN, DCBO.TO

In this summary report, we will take a quick look at the top 5 gainers and losers up or down double digits on the Canadian… Read More »Top 5 Gainers and Losers: RPX.V, NINE.CN, DCBO.TO

In this summary report, we will take a quick look at the top 5 gainers and losers up or down double digits on the Canadian… Read More »Top 5 Gainers and Losers: SVA.TO, BRM.V, COR.V

In this summary report, we will take a quick look at the top 5 gainers and losers up or down double digits on the Canadian… Read More »Top 5 Gainers and Losers: DRY.V, ATE.TO, DN.TO

In this summary report, we will take a quick look at the top 5 gainers and losers up or down double digits on the Canadian… Read More »Top 5 gainers and losers: WIFI.CN, EXN.TO, QIM.CN

Revive Therapeutics (RVV.C) provided an update on their psilocybin development programs today. “Revive is building a specialty psilocybin-based product pipeline to treat mental illness, substance… Read More »Revive Therapeutics (RVV.C) and a psilocybin trial-test progress update

The psychedelics space is loaded with over-valued unicorns and also-rans, making it difficult for investors to find real growth opportunities. Here are some companies in… Read More »Small cap psychedelics stocks – Today’s Idea

Looking at the charts of the Psychedelics sector, they can best be described as a mixed bag. Just like Cannabis, shroom stocks are taking a… Read More »Chart Attack: Psychedelic Stocks Crater, A Technical Roundup MYND.C, MCUR.C, PHRM.C, NEON.C

Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and… Read More »Psychedelics sector in review – Investor Roundtable

Whether you’re curious about taking a psychedelics investment trip or a tie-dyed-in-the-wool public market backer, psychedelics conferences are the best way to keep on top… Read More »Psychedelics conference fever – another sector roundup

PharmaTher (PHRM.C) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for ketamine in the treatment of Amyotrophic… Read More »PharmaTher (PHRM.C) Prepares for Phase 2 Clinical Trial After Receiving FDA Orphan Drug Designation for Ketamine